Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma
To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular c...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2021-12, Vol.11 (1), p.24076-24076, Article 24076 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24076 |
|---|---|
| container_issue | 1 |
| container_start_page | 24076 |
| container_title | Scientific reports |
| container_volume | 11 |
| creator | Lee, Jeong Yeop Lee, Byung Chan Kim, Hyoung Ook Heo, Suk Hee Shin, Sang Soo Jeong, Yong Yeon |
| description | To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC). A total of 55 patients who underwent GA-enhanced MRI and DEB-TACE from January 2014 to December 2018 were included. All MRI features were reviewed by two radiologists. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. Univariate and multivariate logistic regression analyses were used to determine predictive factors of treatment response and DFS, respectively. A total of 27 patients (49.1%) achieved complete response (CR) after one session of treatment. There were no significant differences between the two groups in terms of clinical and laboratory characteristics. Heterogeneous signal intensity in the hepatobiliary phase (HBP) was the only independent predictor of non-CR (odds ratio, 4.807;
p
= 0.048). Recurrent HCC was detected in 19 patients (70.4%) after CR. In the multivariate analysis, elevated serum alpha-fetoprotein (AFP) level (≥ 30 ng/mL) was the only significant parameter associated with DFS (hazard ratio, 2.916;
p
= 0.040). This preliminary study demonstrated that heterogeneous signal intensity in the HBP and high serum AFP were useful predictive factors for poor treatment response and short DFS after DEB-TACE, respectively. |
| doi_str_mv | 10.1038/s41598-021-01839-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8674226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_da9316a8aead4cac99c625b9cfe7e789</doaj_id><sourcerecordid>2610912186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-b50eebb6b98745dc9d906687ce00e6f24a762a714071cb817fc346fb34160ecb3</originalsourceid><addsrcrecordid>eNqNks-KFDEQxhtR3GXdF_AgAS-CtCbpdDq5CDL4Z2BEED2HJF09k6U7GZP0ir6Ar21meh13PYghkCL1q4-q4quqxwS_ILgRLxMjrRQ1pqTGRDSy5veqc4pZW9OG0vu34rPqMqUrXE5LJSPyYXXWMEmI5Py8-rlx1xDRh09rpH2P7Oi8s3pEg_O989uEckD7CL2zGUVI--ATID3kUtPHeYtgnHPhkAHdoxy1TzqWpCsSdgdTgMmE0f3Q2QWPnEc72OscLIzjPOqIrI7W-TDpR9WDQY8JLm_ei-rL2zefV-_rzcd369XrTW1bhnNtWgxgDDdSdKztrewl5lx0FjAGPlCmO051RxjuiDWCdINtGB9MwwjHYE1zUa0X3T7oK7WPbtLxuwraqeNHiFtVBnB2BNVr2RCuhS6jMautlJbT1kg7QAedkEXr1aK1n80EvQVfFjDeEb2b8W6ntuFaCd4xSnkReHYjEMPXGVJWk0uH3WgPYU6KcoIloUQc0Kd_oVdhjr6s6kjRpiOEFYoulI0hpQjDqRmC1cE2arGNKrZRR9uog_ST22OcSn6bpADPF-AbmDAk68BbOGHFV11TrhQl4ocexP_TK5eP1liF2edS2iylqeB-C_HPkP_o_xf-fPHE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610237114</pqid></control><display><type>article</type><title>Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma</title><source>Nature Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Lee, Jeong Yeop ; Lee, Byung Chan ; Kim, Hyoung Ook ; Heo, Suk Hee ; Shin, Sang Soo ; Jeong, Yong Yeon</creator><creatorcontrib>Lee, Jeong Yeop ; Lee, Byung Chan ; Kim, Hyoung Ook ; Heo, Suk Hee ; Shin, Sang Soo ; Jeong, Yong Yeon</creatorcontrib><description>To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC). A total of 55 patients who underwent GA-enhanced MRI and DEB-TACE from January 2014 to December 2018 were included. All MRI features were reviewed by two radiologists. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. Univariate and multivariate logistic regression analyses were used to determine predictive factors of treatment response and DFS, respectively. A total of 27 patients (49.1%) achieved complete response (CR) after one session of treatment. There were no significant differences between the two groups in terms of clinical and laboratory characteristics. Heterogeneous signal intensity in the hepatobiliary phase (HBP) was the only independent predictor of non-CR (odds ratio, 4.807;
p
= 0.048). Recurrent HCC was detected in 19 patients (70.4%) after CR. In the multivariate analysis, elevated serum alpha-fetoprotein (AFP) level (≥ 30 ng/mL) was the only significant parameter associated with DFS (hazard ratio, 2.916;
p
= 0.040). This preliminary study demonstrated that heterogeneous signal intensity in the HBP and high serum AFP were useful predictive factors for poor treatment response and short DFS after DEB-TACE, respectively.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-021-01839-6</identifier><identifier>PMID: 34911966</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4020/4021 ; 692/53/2423 ; 692/699/1503/1607/1610 ; Aged ; Biomarkers, Tumor ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - etiology ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - therapy ; Chemoembolization ; Chemoembolization, Therapeutic - adverse effects ; Chemoembolization, Therapeutic - methods ; Comorbidity ; Disease Management ; Drug delivery ; Female ; Follow-Up Studies ; Hepatocellular carcinoma ; Humanities and Social Sciences ; Humans ; Laboratories ; Liver cancer ; Liver Neoplasms - diagnosis ; Liver Neoplasms - etiology ; Liver Neoplasms - mortality ; Liver Neoplasms - therapy ; Magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Male ; Middle Aged ; multidisciplinary ; Multidisciplinary Sciences ; Multivariate analysis ; Neoplasm Staging ; Odds Ratio ; Patients ; Prognosis ; Retrospective Studies ; Science ; Science & Technology ; Science & Technology - Other Topics ; Science (multidisciplinary) ; Solid tumors ; Treatment Outcome ; Tumor Burden ; α-Fetoprotein</subject><ispartof>Scientific reports, 2021-12, Vol.11 (1), p.24076-24076, Article 24076</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000730739800064</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c540t-b50eebb6b98745dc9d906687ce00e6f24a762a714071cb817fc346fb34160ecb3</citedby><cites>FETCH-LOGICAL-c540t-b50eebb6b98745dc9d906687ce00e6f24a762a714071cb817fc346fb34160ecb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674226/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674226/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27928,27929,41124,42193,51580,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34911966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jeong Yeop</creatorcontrib><creatorcontrib>Lee, Byung Chan</creatorcontrib><creatorcontrib>Kim, Hyoung Ook</creatorcontrib><creatorcontrib>Heo, Suk Hee</creatorcontrib><creatorcontrib>Shin, Sang Soo</creatorcontrib><creatorcontrib>Jeong, Yong Yeon</creatorcontrib><title>Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>SCI REP-UK</addtitle><addtitle>Sci Rep</addtitle><description>To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC). A total of 55 patients who underwent GA-enhanced MRI and DEB-TACE from January 2014 to December 2018 were included. All MRI features were reviewed by two radiologists. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. Univariate and multivariate logistic regression analyses were used to determine predictive factors of treatment response and DFS, respectively. A total of 27 patients (49.1%) achieved complete response (CR) after one session of treatment. There were no significant differences between the two groups in terms of clinical and laboratory characteristics. Heterogeneous signal intensity in the hepatobiliary phase (HBP) was the only independent predictor of non-CR (odds ratio, 4.807;
p
= 0.048). Recurrent HCC was detected in 19 patients (70.4%) after CR. In the multivariate analysis, elevated serum alpha-fetoprotein (AFP) level (≥ 30 ng/mL) was the only significant parameter associated with DFS (hazard ratio, 2.916;
p
= 0.040). This preliminary study demonstrated that heterogeneous signal intensity in the HBP and high serum AFP were useful predictive factors for poor treatment response and short DFS after DEB-TACE, respectively.</description><subject>692/4020/4021</subject><subject>692/53/2423</subject><subject>692/699/1503/1607/1610</subject><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - etiology</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization</subject><subject>Chemoembolization, Therapeutic - adverse effects</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Comorbidity</subject><subject>Disease Management</subject><subject>Drug delivery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hepatocellular carcinoma</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - etiology</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - therapy</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Multidisciplinary Sciences</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Odds Ratio</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Science</subject><subject>Science & Technology</subject><subject>Science & Technology - Other Topics</subject><subject>Science (multidisciplinary)</subject><subject>Solid tumors</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><subject>α-Fetoprotein</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNks-KFDEQxhtR3GXdF_AgAS-CtCbpdDq5CDL4Z2BEED2HJF09k6U7GZP0ir6Ar21meh13PYghkCL1q4-q4quqxwS_ILgRLxMjrRQ1pqTGRDSy5veqc4pZW9OG0vu34rPqMqUrXE5LJSPyYXXWMEmI5Py8-rlx1xDRh09rpH2P7Oi8s3pEg_O989uEckD7CL2zGUVI--ATID3kUtPHeYtgnHPhkAHdoxy1TzqWpCsSdgdTgMmE0f3Q2QWPnEc72OscLIzjPOqIrI7W-TDpR9WDQY8JLm_ei-rL2zefV-_rzcd369XrTW1bhnNtWgxgDDdSdKztrewl5lx0FjAGPlCmO051RxjuiDWCdINtGB9MwwjHYE1zUa0X3T7oK7WPbtLxuwraqeNHiFtVBnB2BNVr2RCuhS6jMautlJbT1kg7QAedkEXr1aK1n80EvQVfFjDeEb2b8W6ntuFaCd4xSnkReHYjEMPXGVJWk0uH3WgPYU6KcoIloUQc0Kd_oVdhjr6s6kjRpiOEFYoulI0hpQjDqRmC1cE2arGNKrZRR9uog_ST22OcSn6bpADPF-AbmDAk68BbOGHFV11TrhQl4ocexP_TK5eP1liF2edS2iylqeB-C_HPkP_o_xf-fPHE</recordid><startdate>20211215</startdate><enddate>20211215</enddate><creator>Lee, Jeong Yeop</creator><creator>Lee, Byung Chan</creator><creator>Kim, Hyoung Ook</creator><creator>Heo, Suk Hee</creator><creator>Shin, Sang Soo</creator><creator>Jeong, Yong Yeon</creator><general>Nature Publishing Group UK</general><general>NATURE PORTFOLIO</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211215</creationdate><title>Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma</title><author>Lee, Jeong Yeop ; Lee, Byung Chan ; Kim, Hyoung Ook ; Heo, Suk Hee ; Shin, Sang Soo ; Jeong, Yong Yeon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-b50eebb6b98745dc9d906687ce00e6f24a762a714071cb817fc346fb34160ecb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/4020/4021</topic><topic>692/53/2423</topic><topic>692/699/1503/1607/1610</topic><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - etiology</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization</topic><topic>Chemoembolization, Therapeutic - adverse effects</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Comorbidity</topic><topic>Disease Management</topic><topic>Drug delivery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hepatocellular carcinoma</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - etiology</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - therapy</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Multidisciplinary Sciences</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Odds Ratio</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Science</topic><topic>Science & Technology</topic><topic>Science & Technology - Other Topics</topic><topic>Science (multidisciplinary)</topic><topic>Solid tumors</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jeong Yeop</creatorcontrib><creatorcontrib>Lee, Byung Chan</creatorcontrib><creatorcontrib>Kim, Hyoung Ook</creatorcontrib><creatorcontrib>Heo, Suk Hee</creatorcontrib><creatorcontrib>Shin, Sang Soo</creatorcontrib><creatorcontrib>Jeong, Yong Yeon</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jeong Yeop</au><au>Lee, Byung Chan</au><au>Kim, Hyoung Ook</au><au>Heo, Suk Hee</au><au>Shin, Sang Soo</au><au>Jeong, Yong Yeon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><stitle>SCI REP-UK</stitle><addtitle>Sci Rep</addtitle><date>2021-12-15</date><risdate>2021</risdate><volume>11</volume><issue>1</issue><spage>24076</spage><epage>24076</epage><pages>24076-24076</pages><artnum>24076</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC). A total of 55 patients who underwent GA-enhanced MRI and DEB-TACE from January 2014 to December 2018 were included. All MRI features were reviewed by two radiologists. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. Univariate and multivariate logistic regression analyses were used to determine predictive factors of treatment response and DFS, respectively. A total of 27 patients (49.1%) achieved complete response (CR) after one session of treatment. There were no significant differences between the two groups in terms of clinical and laboratory characteristics. Heterogeneous signal intensity in the hepatobiliary phase (HBP) was the only independent predictor of non-CR (odds ratio, 4.807;
p
= 0.048). Recurrent HCC was detected in 19 patients (70.4%) after CR. In the multivariate analysis, elevated serum alpha-fetoprotein (AFP) level (≥ 30 ng/mL) was the only significant parameter associated with DFS (hazard ratio, 2.916;
p
= 0.040). This preliminary study demonstrated that heterogeneous signal intensity in the HBP and high serum AFP were useful predictive factors for poor treatment response and short DFS after DEB-TACE, respectively.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34911966</pmid><doi>10.1038/s41598-021-01839-6</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2021-12, Vol.11 (1), p.24076-24076, Article 24076 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8674226 |
| source | Nature Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry |
| subjects | 692/4020/4021 692/53/2423 692/699/1503/1607/1610 Aged Biomarkers, Tumor Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - therapy Chemoembolization Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - methods Comorbidity Disease Management Drug delivery Female Follow-Up Studies Hepatocellular carcinoma Humanities and Social Sciences Humans Laboratories Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - etiology Liver Neoplasms - mortality Liver Neoplasms - therapy Magnetic resonance imaging Magnetic Resonance Imaging - methods Male Middle Aged multidisciplinary Multidisciplinary Sciences Multivariate analysis Neoplasm Staging Odds Ratio Patients Prognosis Retrospective Studies Science Science & Technology Science & Technology - Other Topics Science (multidisciplinary) Solid tumors Treatment Outcome Tumor Burden α-Fetoprotein |
| title | Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T01%3A19%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20MRI%20and%20clinical%20findings%20to%20predict%20response%20after%20drug%20eluting%20bead%20transarterial%20chemoembolization%20in%20hepatocellular%20carcinoma&rft.jtitle=Scientific%20reports&rft.au=Lee,%20Jeong%20Yeop&rft.date=2021-12-15&rft.volume=11&rft.issue=1&rft.spage=24076&rft.epage=24076&rft.pages=24076-24076&rft.artnum=24076&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-021-01839-6&rft_dat=%3Cproquest_pubme%3E2610912186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610237114&rft_id=info:pmid/34911966&rft_doaj_id=oai_doaj_org_article_da9316a8aead4cac99c625b9cfe7e789&rfr_iscdi=true |